Advertisement
Screener

RHYTHM PHARMACEUTICALS, INC. (RYTM) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

RHYTHM PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $10.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-04

  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $16.46M, a 24.15% increase year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$5.62M.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.25M, a 91.73% decline year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $11.02M, a 46.71% increase year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $21.89M, a 0.12% decline from fiscal 2024.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $21.92M, a 48.37% increase from fiscal 2023.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $14.77M, a 857.42% increase from fiscal 2022.
  • RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.54M, a 91.57% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month
2026-06-30$16.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$10.84M
10-Q · filed 2026-08-04
$12.09M
derived: sum of 3 quarters · filed 2026-08-04
$23.11M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$5.62M
10-Q · filed 2026-05-05
-$4.36M
derived: sum of 2 quarters · filed 2026-05-05
$6.65M
derived: sum of 3 quarters · filed 2026-05-05
$19.91M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$1.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$12.27M
derived: sum of 2 quarters · filed 2026-02-26
$25.52M
derived: sum of 3 quarters · filed 2026-08-04
$21.89M
10-K · filed 2026-02-26
2025-09-30$11.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$24.27M
derived: sum of 2 quarters · filed 2026-08-04
$20.64M
10-Q · filed 2025-11-04
$35.82M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$13.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$9.62M
10-Q · filed 2026-08-04
$24.80M
derived: sum of 3 quarters · filed 2026-08-04
$32.31M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$3.63M
10-Q · filed 2026-05-05
$11.55M
derived: sum of 2 quarters · filed 2026-05-05
$19.05M
derived: sum of 3 quarters · filed 2026-05-05
$19.54M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$15.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$22.69M
derived: sum of 2 quarters · filed 2026-02-26
$23.17M
derived: sum of 3 quarters · filed 2026-02-26
$21.92M
10-K · filed 2026-02-26
2024-09-30$7.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$7.99M
derived: sum of 2 quarters · filed 2025-11-04
$6.74M
10-Q · filed 2025-11-04
$11.60M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$482.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$769.00K
10-Q · filed 2025-08-05
$4.09M
derived: sum of 3 quarters · filed 2026-02-26
$8.18M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$1.25M
10-Q · filed 2025-05-07
$3.61M
derived: sum of 2 quarters · filed 2026-02-26
$7.69M
derived: sum of 3 quarters · filed 2026-02-26
$8.36M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$4.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$8.95M
derived: sum of 2 quarters · filed 2026-02-26
$9.61M
derived: sum of 3 quarters · filed 2026-02-26
$14.77M
10-K · filed 2026-02-26
2023-09-30$4.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$4.75M
derived: sum of 2 quarters · filed 2024-11-06
$9.91M
10-Q · filed 2024-11-06
$25.63M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30$661.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$5.83M
10-Q · filed 2024-08-06
$21.54M
derived: sum of 3 quarters · filed 2025-02-28
$8.97M
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31$5.17M
10-Q · filed 2024-05-07
$20.88M
derived: sum of 2 quarters · filed 2025-02-28
$8.31M
derived: sum of 3 quarters · filed 2025-02-28
$6.76M
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31$15.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$3.14M
derived: sum of 2 quarters · filed 2025-02-28
$1.60M
derived: sum of 3 quarters · filed 2025-02-28
$1.54M
10-K · filed 2025-02-28
2022-09-30-$12.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$14.12M
derived: sum of 2 quarters · filed 2023-11-08
-$14.17M
10-Q · filed 2023-11-08
-$1.25M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30-$1.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01
-$1.60M
10-Q · filed 2023-08-01
$11.32M
derived: sum of 3 quarters · filed 2024-02-29
$17.31M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31-$53.00K
10-Q · filed 2023-05-02
$12.87M
derived: sum of 2 quarters · filed 2024-02-29
$18.86M
derived: sum of 3 quarters · filed 2024-02-29
$24.53M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$12.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$18.91M
derived: sum of 2 quarters · filed 2024-02-29
$24.58M
derived: sum of 3 quarters · filed 2024-02-29
$18.31M
10-K · filed 2024-02-29
2021-09-30$5.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$11.66M
derived: sum of 2 quarters · filed 2022-11-08
$5.39M
10-Q · filed 2022-11-08
$7.33M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$5.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
-$598.00K
10-Q · filed 2022-08-03
$1.34M
derived: sum of 3 quarters · filed 2023-03-01
$1.88M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31-$6.27M
10-Q · filed 2022-05-03
-$4.33M
derived: sum of 2 quarters · filed 2023-03-01
-$3.79M
derived: sum of 3 quarters · filed 2023-03-01
-$6.04M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$1.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$2.48M
derived: sum of 2 quarters · filed 2023-03-01
$227.00K
derived: sum of 3 quarters · filed 2023-03-01
-$6.45M
10-K · filed 2023-03-01
2020-09-30$536.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02
-$1.71M
derived: sum of 2 quarters · filed 2021-11-02
-$8.39M
10-Q · filed 2021-11-02
-$8.92M
derived: sum of 4 quarters · filed 2021-11-02
2020-06-30-$2.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
-$8.92M
10-Q · filed 2021-08-03
-$9.46M
derived: sum of 3 quarters · filed 2021-08-03
-$10.69M
derived: sum of 4 quarters · filed 2021-08-03
2020-03-31-$6.67M
10-Q · filed 2021-05-03
-$7.21M
derived: sum of 2 quarters · filed 2021-05-03
-$8.44M
derived: sum of 3 quarters · filed 2021-05-03
$5.91M
derived: sum of 4 quarters · filed 2021-05-03
2019-12-31-$536.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$1.77M
derived: sum of 2 quarters · filed 2021-03-01
$12.58M
derived: sum of 3 quarters · filed 2021-03-01
$10.51M
10-K · filed 2021-03-01
2019-09-30-$1.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
$13.12M
derived: sum of 2 quarters · filed 2020-11-02
$11.04M
10-Q · filed 2020-11-02
$16.77M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$14.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03
$12.27M
10-Q · filed 2020-08-03
$18.00M
derived: sum of 3 quarters · filed 2021-03-01
$18.66M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$2.07M
10-Q · filed 2020-05-04
$3.65M
derived: sum of 2 quarters · filed 2021-03-01
$4.31M
derived: sum of 3 quarters · filed 2021-03-01
$6.10M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$5.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$6.38M
derived: sum of 2 quarters · filed 2021-03-01
$8.17M
derived: sum of 3 quarters · filed 2021-03-01
$6.95M
10-K · filed 2021-03-01
2018-09-30$655.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01
$2.44M
derived: sum of 2 quarters · filed 2019-11-01
$1.22M
10-Q · filed 2019-11-01
$2.34M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$1.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29
$569.00K
10-Q · filed 2019-07-29
$1.69M
derived: sum of 3 quarters · filed 2020-03-02
$2.30M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$1.22M
10-Q · filed 2019-05-03
-$104.00K
derived: sum of 2 quarters · filed 2020-03-02
$514.00K
derived: sum of 3 quarters · filed 2020-03-02
$1.19M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$1.73M
derived: sum of 2 quarters · filed 2020-03-02
$2.41M
derived: sum of 3 quarters · filed 2020-03-02
$1.95M
10-K · filed 2020-03-02
2017-09-30$618.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$1.29M
derived: sum of 2 quarters · filed 2018-11-09
$830.00K
10-Q · filed 2018-11-09
$1.32M
derived: sum of 4 quarters · filed 2019-03-08
2017-06-30$676.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
$212.00K
10-Q · filed 2018-08-08
$707.00K
derived: sum of 3 quarters · filed 2019-03-08
2017-03-31-$464.00K
10-Q · filed 2018-05-14
$31.00K
derived: sum of 2 quarters · filed 2019-03-08
2016-12-31$495.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08
$160.00K
10-K · filed 2019-03-08
2016-09-30-$335.00K
10-Q · filed 2017-11-14
2015-12-31$3.84M
8-K · filed 2018-11-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alkermes plc. (ALKS)$6.844B132.74
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60